GlassScriptPhysician profile
Ralph S Sharman
NPI 1548297096
$6,604.35
in general payments reported to CMS, 2019-2025
38 companies · $1,387 in 2025
The $1,387 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $422 · 2020: $221 · 2021: $1,053 · 2022: $809 · 2023: $1,450 · 2024: $1,263 · 2025: $1,387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,099.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $858.16 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $828.49 | 2021-2025 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $631.59 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $558.06 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $502.07 | 2019-2025 | |
| Novo Nordisk INC | $395.25 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.41 | 2021-2025 | Jardiance, Synjardy |
| Abbott Laboratories | $280.49 | 2019-2025 | Freestyle Libre 3, Octrode, Proclaim |
| Amgen INC. | $231.97 | 2019-2025 | Repatha, Otezla, Evenity |
| Astellas Pharma US INC | $231.60 | 2019-2024 | Veozah, Myrbetriq |
| Bausch Health US, LLC | $217.35 | 2022-2025 | Aplenzin, Wellbutrin |
| Janssen Pharmaceuticals, INC | $205.66 | 2019-2025 | Xarelto, Spravato |
| Exact Sciences Corporation | $152.96 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $130.18 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $118.07 | 2022-2024 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cmp Pharma, INC. | $83.78 | 2022 | |
| Esperion Therapeutics, INC. | $81.74 | 2021-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $77.91 | 2021-2023 | |
| Dexcom, INC. | $77.31 | 2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $76.51 | 2022 | |
| Amarin Pharma, INC. | $73.16 | 2019-2021 | |
| Medtronic, INC. | $70.05 | 2024-2025 | Synchromedii, Intellis Adaptivestim |
| Biohaven Pharmaceutical Holding Company LTD. | $48.96 | 2022 | |
| Allergan, INC. | $40.80 | 2019-2020 | |
| Noven Therapeutics, LLC | $39.14 | 2024 | Xelstrym |
| Merck Sharp & Dohme LLC | $35.74 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.87 | 2022-2023 | Xifaxan |
| Genentech USA, INC. | $34.09 | 2021 | |
| Antares Pharma, INC. | $28.20 | 2019-2023 | Nocdurna, Tlando, Xyosted |
| Lundbeck LLC | $23.40 | 2025 | Vyepti |
| Corium, LLC | $22.58 | 2025 | Azstarys |
| Cranial Technologies, INC | $20.53 | 2023 | Doc Band |
| Sanofi-Aventis U.S. LLC | $19.86 | 2019 | |
| Shield Therapeutics INC | $18.27 | 2023 | Accrufer |
| Tolmar, INC. | $15.99 | 2025 | Jatenzo |
| Amneal Pharmaceuticals LLC | $15.60 | 2020 | |
| Shire North American Group INC | $14.85 | 2019 | |
| Irhythm Technologies, INC. | $12.70 | 2023 | Zio Xt Patch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Sharman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.